Fig 7. Differences in the expression of estrogen receptor alpha (ERa), phosphorylated estrogen receptor alpha at serine 118 (P-Ser118 ER), and GAPDH during selection for survival in the absence or presence of increasing concentrations (doses) of doxorubicin (selection doses 7 through 11).

Immunoblots were conducted using extracts of cells without or with a treatment with 100 nM E2. Primary antibodies purchased from Cell Signaling and used at 1:1000 dilution in 0.5% BSA overnight at 4°C. (A) Representative western blots for Era and GAPDH. (B) Data for P-Ser118 ER is expressed relative to untreated (NT) MCF-7_CC-12 cells. (C) Data for ERa is expressed relative to untreated (NT) MCF-7_CC-12 cells. All expression values were first normalized to GAPDH expression. Bars represent the mean ± S.E.M. for three independent experiments. The significance of differences between the test sample and that of treated or untreated MCF-7_CC-12 cells was assessed using an ANOVA test, followed by Bonferoni correction. * p< 0.05,** p< 0.01, *** p< 0.001